ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: biosimilars

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

  |  

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…

4 Rheumatoid Arthritis Therapy Principles, & New Drug Info

  |  

CHICAGO—Amid what she called a “dizzying array of choices” for rheumatoid arthritis (RA)—from anti-TNF and anti-IL6-receptor therapies to B cell depletion to new biosimilar options—disease treatment should still revolve around several basic concepts, an expert said at the ACR State-of-the-Art Clinical Symposium in April. Joan Bathon, MD, chief of rheumatology at Columbia University in New…

ACR & NPF Highlight Medicare Access Challenges in Capitol Hill Briefing

  |  

Concerns about how the Trump administration’s ideas to lower drug prices could reduce patient access to medicines led the ACR to speak out on many different fronts. On June 25, at a briefing hosted by the ACR and the National Psoriasis Foundation (NPF), a packed room of Congressional staffers and reporters learned from rheumatologists and…

ACR Responds to Drug Pricing Proposals

  |  

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…

ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed

Angus Worthing  |  

Greetings, Advocates! In my last update, I described the great news from February’s budget agreement that fixed Medicare’s payment adjustments so MIPS penalties would not include Part B drug costs, ensuring stabilization of the Medicare Part B drug system, among other successes. (Read the ACR’s press release on this topic.) I also described the Trump administration’s…

ACR’s Affiliate Society Council Reports Solid Gains in Advocacy Efforts

  |  

It’s May, and soon, most state legislatures will be adjourning for the remainder of the year. Joseph Cantrell, JD, senior manager of state affairs for the ACR, who tracks the progress of state and federal patient care legislation, reports that several states saw solid gains during 2018 state sessions, which typically run from January to…

Gap in Regulating Biotech Drug Copies Prompts WHO to Step In

Ben Hirschler  |  

LONDON (Reuters)—Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike -but uneven regulation has created a lopsided market. Now the World Health Organization (WHO) is stepping in to assess the quality of such so-called biosimilars, offering a global stamp of approval…

New Life for the Michigan Rheumatism Society

  |  

Amar Majjhoo, MD, had just completed his rheumatology fellowship in 2005 when he attended his first meeting of the Michigan Rheumatism Society. “I thought it was exciting that we had a state society, because to me, everything was new,” says the Michigan-based, private practice rheumatologist. “Having a meeting where established doctors were sitting around was…